Editorial Note: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma: Role of Angiotensin (1–7)
2024
Olmesartan and Sorafenib in Cancer Treatment
Editorial
Author Information
Author(s): The PLOS ONE Editors
Conclusion
The editorial discusses concerns about discrepancies in methods and results related to the anti-angiogenic effects of olmesartan and sorafenib.
Takeaway
This article talks about how two cancer treatments might work better together, but there were some questions about the research methods.
Limitations
Concerns were raised about discrepancies in methods and results, and some details were not clarified.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website